PlainRecalls
FDA Drug Low Class III Terminated

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Reported: March 15, 2017 Initiated: February 17, 2017 #D-0511-2017

Product Description

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Reason for Recall

Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
25,916 cartons
Distribution
Nationwide in the United States and Puerto Rico
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.. Recalled by Teva Pharmaceuticals USA. Units affected: 25,916 cartons.
Why was this product recalled?
Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 15, 2017. Severity: Low. Recall number: D-0511-2017.